NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
09/13/2024
Back to search
Official data from USPTO
ABACCEL
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
28
Latest update
09/13/2024
Classification
Registered
Trademark type
Word
Nice classes
42
Filing date
04/11/2016
Registration date
09/12/2017
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
09/13/2024
Last transaction
09/13/2024
Responsible office
United States Patent and Trademark Office
Status code
702
Official register
Principal Register
Filing basis
Foreign priority
Drawing code
4
Owner type
16
Owner location
Plzen, CZ
Examiner
O'ROURKE, JONATHAN RYAN
Current location
FILE DESTROYED
Holders and representatives
Holders
A. S. (pessoa física)
Representatives
Karen L. Elbing CLARK & ELBING LLP
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Scientific and technological services and research projects for the preparation of peptide and antibody librariesfor the identification and characterisation of binding moleculesnamely scientific research and analysis in the field of antibody research and antibody optimization; scientific and technological services and research projects for the preparationidentification and characterisation of peptides or antibodiesnamely scientific research and analysis in the field of antibody research and antibody optimization; scientific and technological services and research projects for the preparationidentification and characterisation of recombinant antibodiessingle-chain antibodiesdiabodiestandabsflexibodiestriabodiestetrabodiesbivalent antibodiesmultivalent antibodieswhole immunoglobulinsantibody fragmentsin particular Fab and scFv fragmentsof nucleic acid sequences coding for these moleculesnamely scientific research and analysis in the field of antibody research and antibody optimization; scientific and technological services and research projects in relation to batch-cloning and screening of naturalengineered and immunized librariesnamely scientific research and analysis in the field of antibody research and antibody optimization; scientific and technological services and research projects in relation to batch-cloning and screening of antibody librariesnamely scientific research and analysis in the field of antibody research and antibody optimization; scientific and technological services and research projects in relation to antibody development strategiesnamely scientific research and analysis in the field of antibody research and antibody optimization; scientific and technological services and research projects in relation to the optimizationmaturation and humanization of antibody drug candidatesnamely scientific research and analysis in the field of antibody research and drug design; scientific and technological services and research projects in relation to multi-factor antibody optimizationnamely scientific research and analysis in the field of antibody research and drug design; scientific and technological services and research projects in relation to the optimization of antibody binding affinityantibody stabilityspecies cross-reactivityspecificitydevelopabilityproducibilityhuman propertiesnamely scientific research and analysis in the field of antibody research and antibody optimization; scientific and technological services and research projects in relation to human and nonhuman lead antibody technologynamely scientific research and analysis in the field of antibody research and antibody optimization
Publications
History of USPTO decisions and trademark events.
28 publications found
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
09/13/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
09/13/2024
E815
TEAS SECTION 8 & 15 RECEIVED
03/06/2024
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
09/12/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
09/12/2017
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/27/2017
PUBO
PUBLISHED FOR OPPOSITION
06/27/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/07/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/04/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/13/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/12/2017
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
04/12/2017
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
03/24/2017
GNFR
FINAL REFUSAL E-MAILED
03/24/2017
CNFR
FINAL REFUSAL WRITTEN
03/24/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/23/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/23/2017
ALIE
ASSIGNED TO LIE
02/16/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/01/2017
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/03/2016
GNRT
NON-FINAL ACTION E-MAILED
08/03/2016
CNRT
NON-FINAL ACTION WRITTEN
08/03/2016
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
07/29/2016
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
07/29/2016
DOCK
ASSIGNED TO EXAMINER
07/26/2016
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/15/2016
NWAP
NEW APPLICATION ENTERED
04/14/2016
Continuous trademark protection
Get notified about every new filing that threatens ABACCEL or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.